Search Results for "Contraceptives"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contraceptives. Results 151 to 160 of 263 total matches.
Afatinib (Gilotrif) for Advanced Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • May 25, 2015 (Issue 1469)
anomalies in rats). Women of child-bearing
age should use highly effective contraception during
treatment ...
The FDA has approved afatinib (Gilotrif — Boehringer
Ingelheim), an oral epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor, for first-line treatment
of patients with metastatic non-small cell lung cancer
(NSCLC) whose tumors have EGFR exon 19 deletions
or exon 21 (L858R) substitution mutations. These
mutations occur in about 10% of patients with NSCLC.
Afatinib is the second EGFR inhibitor to be approved
for first-line treatment of advanced lung cancer. The
first was erlotinib (Tarceva), which is also approved
for treatment of patients with locally advanced...
Lenvatinib (Lenvima) for Thyroid Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Aug 17, 2015 (Issue 1475)
who could become
pregnant should use effective contraception during
treatment with lenvatinib ...
The FDA has approved the oral multikinase inhibitor
lenvatinib (Lenvima – Eisai) for treatment of locally
recurrent or metastatic, progressive, differentiated
thyroid cancer (papillary or follicular) refractory to
radioactive iodine treatment.
Copanlisib (Aliqopa) for Relapsed Follicular Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 23, 2018 (Issue 1545)
contraception during treatment and for at
least one month after the last dose. Lactating women
should ...
The FDA has granted accelerated approval to copanlisib
(Aliqopa – Bayer), an intravenously administered
phosphatidylinositol 3-kinase (PI3K) inhibitor, for
treatment of adults with relapsed follicular lymphoma
who have received at least two prior systemic
therapies. Follicular lymphoma is a common subtype
of non-Hodgkin's lymphoma. Copanlisib is the second
PI3K inhibitor to be approved for this indication;
idelalisib (Zydelig), which is administered orally twice
daily, was the first.
Pemigatinib (Pemazyre) for Cholangiocarcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
partners should use effective contraception
during treatment with pemigatinib and for 1 week after ...
The oral kinase inhibitor pemigatinib (Pemazyre –
Incyte) has received accelerated approval from
the FDA for treatment of adults with previously
treated, unresectable, locally advanced or metastatic
cholangiocarcinoma with fibroblast growth factor
receptor 2 (FGFR2) fusions or other rearrangements.
Pemigatinib is the first drug to be approved in the US
for this indication.
Teprotumumab (Tepezza) for Thyroid Eye Disease
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
.
Women of childbearing potential should use effective
contraception before starting treatment, during ...
Teprotumumab-trbw (Tepezza - Horizon), an insulin-like
growth factor-1 receptor (IGF-1R) inhibitor, has
been approved by the FDA for IV treatment of thyroid
eye disease. It is the first drug to be approved in the US
for this indication.
Amivantamab (Rybrevant) for Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
use effective contraception during
treatment with amivantamab and for 3 months after
the last dose ...
Amivantamab-vmjw (Rybrevant – Janssen), an EGFR-MET
bispecific antibody, has received accelerated
approval from the FDA for IV treatment of locally
advanced or metastatic non-small cell lung cancer
(NSCLC) with epidermal growth factor receptor
(EGFR) exon 20 insertion mutations in adults whose
disease has progressed on or after platinum-based
chemotherapy. It is the first bispecific antibody
to become available in the US for this indication.
Accelerated approval of the drug was based on the
overall response rate and duration of response.
Teclistamab-cqyv (Tecvayli) For Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
of
childbearing potential should use effective contraception
during treatment with teclistamab and for
5 months ...
Teclistamab-cqyv (Tecvayli – Janssen), a bispecific
B-cell maturation antigen (BCMA)-directed CD3
T-cell engager, has been granted accelerated
approval by the FDA for treatment of relapsed or
refractory multiple myeloma in adults who received
≥4 prior lines of therapy, including a proteasome
inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Accelerated approval
was based on response rate. Teclistamab is the first
bispecific BCMA-directed CD3 T-cell engager to be
approved in the US.
Glofitamab (Columvi) for Diffuse Large B-Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
should use effective
contraception during treatment with glofitamab and
for 1 month after the last dose ...
Glofitamab-gxbm (Columvi – Genentech), a bispecific
CD20-directed CD3 T-cell engager, has received
accelerated approval from the FDA for IV treatment of
relapsed or refractory diffuse large B-cell lymphoma
(DLBCL), not otherwise specified, or large B-cell
lymphoma (LBCL) arising from follicular lymphoma
after ≥2 lines of systemic therapy. Accelerated
approval was based on response rates and durability
of response. Glofitamab is the second T-cell-engaging
bispecific antibody to be approved in the US
for treatment of DLBCL; epcoritamab-bysp (Epkinly),
which is given...
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e129-30 doi:10.58347/tml.2023.1682b | Show Introduction Hide Introduction
Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019 (Issue 1581)
who are pregnant. Women of
childbearing potential should use effective contraception during ...
Lefamulin (Xenleta – Nabriva), a semisynthetic
pleuromutilin antibiotic, has been approved by the
FDA for IV and oral treatment of community-acquired
bacterial pneumonia (CABP) in adults. It is the first
systemic pleuromutilin antibiotic to be approved in the
US; retapamulin (Altabax), a 1% topical ointment for
treatment of impetigo, was approved in 2007.
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
contraceptives can increase serum
concentrations of ethinyl estradiol and levonorgestrel.
Leflunomide can ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of
adults in the US; it is about 2.5 times more common
in women than in men. Guidelines for treatment
of RA from the American College of Rheumatology
were recently updated. The goal of treatment is to
minimize disease activity and prevent irreversible
joint damage.